Status:
TERMINATED
MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Migraine
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
A study to assess the safety and efficacy of MK0974 for preventing migraines in patients with episodic migraine.
Eligibility Criteria
Inclusion
- Patient is 18 years of age or older
- Patient has had a history of migraine with or without aura
- Patient is able to complete study questionnaire(s) and paper diary
Exclusion
- Patient is pregnant or breast-feeding, or is a female expecting to conceive within the projected duration of the study
- Patient has basilar or hemiplegic migraine headache, hepatitis or psychiatric conditions
- Patient was older than 50 years of age at migraine onset
- History of gastric or small intestinal surgery or has a disease that causes malabsorption
- Patient has heart attack, unstable angina, coronary artery bypass surgery or other revascularization procedure, stroke, or transient ischemic attack 3 months before starting the study
- Currently participating or has participated in a study with an investigational compound or device within 30 days of starting the study
- Currently participating in a study with MK-0974 or MK-3207
Key Trial Info
Start Date :
November 12 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 20 2009
Estimated Enrollment :
660 Patients enrolled
Trial Details
Trial ID
NCT00797667
Start Date
November 12 2008
End Date
May 20 2009
Last Update
October 18 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.